A Novel Investigational PD-1 x VEGF Bispecific Antibody for Patients With Cancer
Explore our clinical trials, which are evaluating a study
medicine, PF-08634404, for different types of cancer.
This page is intended for healthcare professionals only.
A Novel Investigational PD-1 x VEGF Bispecific Antibody for Patients With Cancer
Explore our clinical trials, which are evaluating a study medicine, PF-08634404, for different types of cancer.
This page is intended for healthcare professionals only.
About the study medicine
Pfizer is investigating a study medicine, PF-08634404, which is a bispecific antibody that was designed to target both PD-1 and VEGF to potentially block immune checkpoints and inhibit angiogenesis. This dual mechanism has the potential to achieve tumor immunosurveillance, while disrupting vascular support for tumor progression, compared with blocking either target alone in patients with solid tumors.
The study medicine is currently being studied in various cancer types, including lung, colorectal, urothelial, renal, and hepatocellular carcinomas, as well as other advanced solid tumors.
Our clinical trials
Explore Pfizer’s novel investigational PD-1 x VEGF bispecific antibody program, which is a series of clinical trials evaluating a bispecific antibody that was designed to target both PD-1 and VEGF.
C6461001: Investigating a bispecific antibody for locally advanced or metastatic non-small cell lung cancer
A Phase 3 clinical trial evaluating PF-08634404 combined with chemotherapy or pembrolizumab combined with chemotherapy for first-line treatment of locally advanced or metastatic non-small cell lung cancer in your patients who are not candidates for surgical resection and curative concurrent/sequential chemoradiotherapy.
Symbiotic-Lung-10: Investigating a bispecific antibody for early-stage or locally advanced non-small cell lung cancer (NSCLC)
A Phase 2 clinical trial evaluating PF-08634404 as monotherapy or in combination regimens as neoadjuvant, adjuvant, and consolidation therapy for your patients with early-stage resectable or locally advanced unresectable NSCLC, regardless of disease histology.